Sanguine Achieves Triple ISO Certifications for Excellence in Quality, Security, and Privacy
Sanguine has successfully attained ISO 9001, ISO 27001, and ISO 27701 certifications. These internationally recognized certifications demonstrate our rigorous approach to quality management, data protection, and privacy practices, setting us apart as a leader in the biospecimen research field.
By obtaining ISO 9001, we underscore our dedication to maintaining robust quality management systems (QMS), ensuring the highest level of service and reliability for our clients. The ISO 27001 certification highlights our focus on protecting sensitive health data through secure information management practices, while ISO 27701 further affirms its commitment to stringent privacy standards in handling donor information.
Precision and Quality: GMP-Grade Leukopaks Launching Soon
We are gearing up to launch GMP-grade leukopaks, designed to meet the stringent standards of Good Manufacturing Practice (GMP). These high-quality immune cell collections offer a consistent and reliable cell source, backed by comprehensive donor data from reserved donors.
Tracking Success: How Longitudinal Studies Shape Vaccine Research
Explore how longitudinal vaccine studies provide insights into vaccine efficacy, safety, and long-term durability. Our blog delves into how tracking participants over time offers invaluable data. Discover real-world examples from the literature that highlight the importance of ongoing time points in understanding vaccine performance, and see how Sanguine’s unique connection with our donors drives success in these groundbreaking studies.
Our inventory has healthy controls and over 50 conditions, including lupus, asthma, diabetes, ovarian cancer, COPD, and Crohn’s disease. PBMCs, plasma, and serum are ready to ship from our freezer to yours to accelerate your biomarker research.
Development of an Enzyme-Linked Immunosorbent Spot Assay for the Assessment of Adeno-Associated Virus Peptides to Examine Immune Safety
Researchers from Boehringer Ingelheim used PBMCs isolated from whole blood collected by Sanguine to develop an assay for monitoring human immune response to AAV peptides.
MOG-specific CAR-Tregs: a novel approach to treat multiple sclerosis
Researchers from Sangamo Therapeutics used PBMCs from donors with multiple sclerosis (MS) collected by Sanguine to examine the feasibility of developing a cell therapy using CAR-Tregs cells.
